415 related articles for article (PubMed ID: 16140928)
21. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
Mathas S; Hinz M; Anagnostopoulos I; Krappmann D; Lietz A; Jundt F; Bommert K; Mechta-Grigoriou F; Stein H; Dörken B; Scheidereit C
EMBO J; 2002 Aug; 21(15):4104-13. PubMed ID: 12145210
[TBL] [Abstract][Full Text] [Related]
22. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
23. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
[TBL] [Abstract][Full Text] [Related]
24. Hodgkin disease with subsequent transformation to CD30 positive non-hodgkin lymphoma in six patients.
Mori N; Watanabe K; Yamashita Y; Nakayama A; Yatabe Y; Narita M; Kobayashi T; Hasegawa Y; Kojima H; Nagasawa T
Cancer; 1999 Feb; 85(4):970-9. PubMed ID: 10091777
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
26. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
27. The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma.
Nakashima M; Ishii Y; Watanabe M; Togano T; Umezawa K; Higashihara M; Watanabe T; Horie R
Cancer Sci; 2010 Nov; 101(11):2490-6. PubMed ID: 20735433
[TBL] [Abstract][Full Text] [Related]
28. Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deficient IL-2 gene expression in Wiskott-Aldrich syndrome.
Cianferoni A; Massaad M; Feske S; de la Fuente MA; Gallego L; Ramesh N; Geha RS
J Allergy Clin Immunol; 2005 Dec; 116(6):1364-71. PubMed ID: 16337472
[TBL] [Abstract][Full Text] [Related]
29. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
[TBL] [Abstract][Full Text] [Related]
30. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
[TBL] [Abstract][Full Text] [Related]
32. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma.
Watanabe M; Ogawa Y; Itoh K; Koiwa T; Kadin ME; Watanabe T; Okayasu I; Higashihara M; Horie R
Lab Invest; 2008 Jan; 88(1):48-57. PubMed ID: 17965727
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
34. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
35. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
36. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
Wright CW; Rumble JM; Duckett CS
J Biol Chem; 2007 Apr; 282(14):10252-62. PubMed ID: 17261581
[TBL] [Abstract][Full Text] [Related]
37. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
Damm-Welk C; Schieferstein J; Schwalm S; Reiter A; Woessmann W
Br J Haematol; 2007 Aug; 138(4):459-66. PubMed ID: 17608768
[TBL] [Abstract][Full Text] [Related]
39. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.
Nonaka M; Horie R; Itoh K; Watanabe T; Yamamoto N; Yamaoka S
Oncogene; 2005 Jun; 24(24):3976-86. PubMed ID: 15782119
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
